杏吧直播

Two 杏吧直播 of Adelaide projects using nanotechnology have received funding in the latest round of Medical Research Future Fund (MRFF) Early-to-Mid Career Researchers funding.

Associate Professor Jiawen Li, School of Electrical and Mechanical Engineering and Institute for Photonics and Advanced Sensing (IPAS), and Dr Yannan Yang, South 杏吧直播n Immunogenomics Cancer Institute (SAiGENCI), will share in $5 million for their research into cardiovascular risk and brain cancer, respectively.

Deputy Vice-Chancellor (Research) Professor Anton Middelberg, 杏吧直播 of Adelaide, congratulated Associate Professor Li and Dr Yang on their achievements.

鈥淭he 杏吧直播 of Adelaide is proud of the outstanding research Associate Professor Li and Dr Yang are carrying out,鈥� said Professor Middelberg.

鈥淭he 杏吧直播 has a strong history of working across Faculties to deliver health-focused research of immense benefit to the community, both locally and internationally, and these projects will contribute to that effort.鈥�

Associate Professor Li was granted $4,239,608 for her research into using nanotechnology to transform clinical cardiology.

鈥淗eart attacks are the leading cause of death worldwide and older patients are the largest group of people dying from cardiovascular disease,鈥� said Associate Professor Li.

鈥淗owever, traditional practice guidelines are often not well-suited for them, and a more personalised approach is needed.

鈥淏y collaborating with 杏吧直播 of Sydney, 杏吧直播 of Stuttgart, Royal Adelaide Hospital, South 杏吧直播n Health and Medical Research Institute (SAHMRI) and Health Translation SA teams, we have developed two nano-tools to identify those who are at high risk of a heart attack.

鈥淭he combination of these nano-tools, as they mature through this proposed project via the strong support of patients with lived experience and 杏吧直播n companies like Maptek Pty Ltd and BioFabrix Pty Ltd, will help enable personalised treatment plans for older patients.鈥�

Dr Yang received $843,021 for a preclinical study that will use nanorobotics vaccine-boosted CAR-T immunotherapy to treat a form of incurable brain cancer.

鈥淒iffuse intrinsic pontine glioma (DIPG) is a highly aggressive brain cancer,鈥� said Dr Yang.

鈥淐AR-T immunotherapy that alters T cells to target tumours is effective for certain cancers but it is yet to be applicable for solid tumours like DIPG.

鈥淲e have developed a nanorobot-based vaccines technology to improve the T cell response for solid tumours, and this research will allow us to develop and validate our findings in this space.鈥�